51
|
Mongereau M, Lheure C, Guegan S, Franck N, Paepegaey AC, Dohan A, Isnard C, Seta V, Chanal J, Dupin N, Aractingi S, Kramkimel N. Hypophysites sous immunothérapie : une complication potentiellement grave à ne pas méconnaître. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
52
|
Richard MA, Joly P, Aractingi S, Auquier P, Le Guen S, Mahé E. Évaluation de l’efficacité du sécukinumab pour le traitement de localisations particulières du psoriasis à l’aide de l’Indice Simplifié du Psoriasis. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
53
|
Raynal M, Lheure C, Seta V, Chanal J, Franck N, Sarah G, Dupin N, Aractingi S, Meyer N, Kramkimel N. Traitement de mélanomes métastatiques avec mutation de NRAS par inhibiteur de MEK après échec de l’immunothérapie. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
54
|
Rosenzwajg M, Lorenzon R, Cacoub P, Pham HP, Pitoiset F, El Soufi K, RIbet C, Bernard C, Aractingi S, Banneville B, Beaugerie L, Berenbaum F, Champey J, Chazouilleres O, Corpechot C, Fautrel B, Mekinian A, Regnier E, Saadoun D, Salem JE, Sellam J, Seksik P, Daguenel-Nguyen A, Doppler V, Mariau J, Vicaut E, Klatzmann D. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis 2018; 78:209-217. [DOI: 10.1136/annrheumdis-2018-214229] [Citation(s) in RCA: 181] [Impact Index Per Article: 30.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2018] [Revised: 10/29/2018] [Accepted: 11/01/2018] [Indexed: 12/12/2022]
Abstract
ObjectiveRegulatory T cells (Tregs) prevent autoimmunity and control inflammation. Consequently, any autoimmune or inflammatory disease reveals a Treg insufficiency. As low-dose interleukin-2 (ld-IL2) expands and activates Tregs, it has a broad therapeutic potential.AimWe aimed to assess this potential and select diseases for further clinical development by cross-investigating the effects of ld-IL2 in a single clinical trial treating patients with 1 of 11 autoimmune diseases.MethodsWe performed a prospective, open-label, phase I–IIa study in 46 patients with a mild to moderate form of either rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, psoriasis, Behcet’s disease, granulomatosis with polyangiitis, Takayasu’s disease, Crohn’s disease, ulcerative colitis, autoimmune hepatitis and sclerosing cholangitis. They all received ld-IL2 (1 million IU/day) for 5 days, followed by fortnightly injections for 6 months. Patients were evaluated by deep immunomonitoring and clinical evaluation.Resultsld-IL2 was well tolerated whatever the disease and the concomitant treatments. Thorough supervised and unsupervised immunomonitoring demonstrated specific Treg expansion and activation in all patients, without effector T cell activation. Indication of potential clinical efficacy was observed.ConclusionThe dose of IL-2 and treatment scheme used selectively activate and expand Tregs and are safe across different diseases and concomitant treatments. This and preliminary indications of clinical efficacy should licence the launch of phase II efficacy trial of ld-IL2 in various autoimmune and inflammatory diseases.Trial registration numberNCT01988506.
Collapse
|
55
|
Samimi M, Dreno B, Aractingi S, Beylot-Barry M, Bodemer C, Chosidow O, Cribier B, Lacour JP, Paul C, Richard MA, Gaudy-Marqueste C, Soria A. [On the attractiveness of a university-hospital career in medicine: Obstacles and solutions. The teachers' perspective]. Ann Dermatol Venereol 2018; 145:196-199. [PMID: 29241631 DOI: 10.1016/j.annder.2017.10.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2017] [Accepted: 10/13/2017] [Indexed: 11/29/2022]
|
56
|
Gaudy-Marqueste C, Samimi M, Soria A, Aractingi S, Bodemer C, Chosidow O, Cribier B, Lacour JP, Paul C, Richard MA, Beylot-Barry M, Dreno B. [Guide to university hospital careers in dermatology. The GRENT (Graines Engrais Tuteurs - Seed Fertilizer Plant stick) Program]. Ann Dermatol Venereol 2018; 145:200-209. [PMID: 29449018 DOI: 10.1016/j.annder.2017.11.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
57
|
Chapalain M, Goldman-Lévy G, Kramkimel N, Carlotti A, Franck N, Lheure C, Audard V, Avril MF, Marcelin AG, Damotte D, Terris B, Aractingi S, Dupin N. Anaplastic Kaposi's sarcoma: 5 cases of a rare and aggressive type of Kaposi's sarcoma. Ann Dermatol Venereol 2017; 145:21-28. [PMID: 29290414 DOI: 10.1016/j.annder.2017.09.593] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2017] [Revised: 09/15/2017] [Accepted: 09/21/2017] [Indexed: 11/27/2022]
Abstract
BACKGROUND Anaplastic Kaposi's sarcoma (KS) is a rare form of KS characterized clinically by the development of a tumour mass with unusual local aggressiveness and histologically by a specific architecture and cytological morphology. A very small number of limited series in endemic countries have established characteristics common to these anaplastic forms of KS. We present five patients with an anaplastic form in a context of KS ongoing for several years in a non-endemic country. MATERIALS AND METHODS We collected 5 cases of anaplastic KS followed in our department over a period of 20years. We describe the main developmental, clinical, virological and histological features. RESULTS The cases involved 4 men and 1 woman whose mean age at diagnosis of anaplastic KD was 70years, with an average time of 25years between initial diagnosis of KD and anaplastic transformation. Our patients were all treated with chemotherapy and/or radiotherapy (RT) prior to diagnosis of anaplastic transformation. All patients had a tumour mass of the lower limbs developing in classically indolent KS with associated chronic lymphoedema. Progression was very aggressive locally with deep invasion of the soft tissues as well as osteoarticular involvement, without visceral dissemination. At present, three patients are dead, one patient is showing partial response, and one patient is in locoregional progression. Diagnosis of the disease was based on histopathological findings. The tumour cells were undifferentiated, pseudo-cohesive, and chiefly organized in sheets. The mitotic count was high (27 mitoses per 10 fields at high magnification). Necrosis was constant. DISCUSSION To our knowledge, this is the first series describing anaplastic Kaposi's sarcoma in a non-endemic country. The severity of the prognosis, despite the absence of visceral dissemination, is related to the local aggressiveness of anaplastic KS and to its resistance to radiotherapy and chemotherapy, with amputation being required in certain cases.
Collapse
|
58
|
Lheure-Barbier C, Kramkimel N, Plee J, Franck N, Goldman-Levy G, Vanhaecke C, Dupin N, Aractingi S, Grange F, Guegan S. Mélanomes primitifs localement avancés et inopérables en rémission complète après traitement néoadjuvant par anti-PD1 : 3 cas. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
59
|
Bataille P, Lheure C, Blanchet B, Franck N, Kramkimel N, Guegan S, Aractingi S, Dupin N. Toxicité cutanée secondaire à une surexposition au tramétinib prescrit en monothérapie. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
60
|
Aractingi S. [Dermatology in the elderly]. LA REVUE DU PRATICIEN 2017; 67:1075. [PMID: 30512603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
|
61
|
Say M, Dupin N, Stieltjes N, Avril MF, Aractingi S, Chanal J. [Dermatologic surgery, hemophilia and Von Willebrand disease]. Ann Dermatol Venereol 2017; 145:233-239. [PMID: 29150153 DOI: 10.1016/j.annder.2017.10.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2017] [Revised: 08/02/2017] [Accepted: 10/03/2017] [Indexed: 11/24/2022]
Abstract
BACKGROUND Von Willebrand disease (VWD) and hemophilia A and B are the most common types of hereditary coagulation-factor deficiencies. The frequency and type of complications of skin surgery in these patients are unknown. The increasing incidence of skin cancer prompted us to reflect upon this issue. While the incidence of skin cancer is increasing, the complications of skin surgery or ablative laser treatment remain unknown in this population. AIM The aim of this study was to determine the frequency of bleeding complications during and after skin surgery in patients with a hereditary coagulation-factor deficiency (hemophilia or VWD). PATIENTS AND METHODS We conducted a retrospective study in patients with hemophilia A or B or VWD undergoing skin surgery or ablative laser treatment at the Dermatology Department of the Cochin Hospital in Paris, France. RESULTS Fourteen procedures were performed in 8 patients. Three episodes of bleeding occurred (n=3/14, 21.4%): one hematoma, one delayed bleed and one immediate bleed. None of these complications required surgical revision or resuscitation. DISCUSSION The rate of hemorrhagic complications was higher than in the general population. However, these complications can be considered non-serious and the risk-benefit ratio remains favorable. Multidisciplinary management and coordination with the reference hemophilia center are mandatory in this population to establish a coagulation-factor (CF) substitution protocol suited to the disease characteristics and the surgical procedure.
Collapse
|
62
|
Frumholtz L, Laurent-Roussel S, Aumaître O, Maurier F, Le Guenno G, Carlotti A, Dallot A, Kemeny JL, Antunes L, Froment N, Fraitag S, London J, Berezne A, Terris B, Le Jeunne C, Mouthon L, Aractingi S, Guillevin L, Dupin N, Terrier B. Clinical and pathological significance of cutaneous manifestations in ANCA-associated vasculitides. Autoimmun Rev 2017; 16:1138-1146. [DOI: 10.1016/j.autrev.2017.09.009] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2017] [Accepted: 08/16/2017] [Indexed: 01/22/2023]
|
63
|
Castela M, Sbeih M, Nassar D, Jachiet M, Wang Z, Aractingi S. 658 Low-dose CCL2 allows the rescue of maternal delayed healing through fetal progenitor cells recruitment. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.335] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
64
|
Vanhaecke C, Deilhes F, Chanal J, Regnier-Rosencher E, Boitier F, Boulinguez S, Avril MF, Guégan S, Dupin N, Aractingi S, Meyer N, Kramkimel N. BRAF V600 inhibitor discontinuation after complete response in advanced melanoma: a retrospective analysis of 16 patients. Br J Dermatol 2017; 177:e94-e95. [DOI: 10.1111/bjd.15345] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
65
|
|
66
|
Castela M, Nassar D, Sbeih M, Jachiet M, Wang Z, Aractingi S. Ccl2/Ccr2 signalling recruits a distinct fetal microchimeric population that rescues delayed maternal wound healing. Nat Commun 2017; 8:15463. [PMID: 28516946 PMCID: PMC5477505 DOI: 10.1038/ncomms15463] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2016] [Accepted: 03/31/2017] [Indexed: 12/20/2022] Open
Abstract
Foetal microchimeric cells (FMCs) traffic into maternal circulation during pregnancy and persist for decades after delivery. Upon maternal injury, FMCs migrate to affected sites where they participate in tissue healing. However, the specific signals regulating the trafficking of FMCs to injury sites had to be identified. Here we report that, in mice, a subset of FMCs implicated in tissue repair displays CD11b+ CD34+ CD31+ phenotype and highly express C-C chemokine receptor 2 (Ccr2). The Ccr2 ligand chemokine ligand 2 (Ccl2) enhances the recruitment of FMCs to maternal wounds where these cells transdifferentiate into endothelial cells and stimulate angiogenesis through Cxcl1 secretion. Ccl2 administration improves delayed maternal wound healing in pregnant and postpartum mice but never in virgin ones. This role of Ccl2/Ccr2 signalling opens new strategies for tissue repair through natural stem cell therapy, a concept that can be later applied to other types of maternal diseases.
Collapse
|
67
|
Castela M, Linay F, Roy E, Moguelet P, Xu J, Holzenberger M, Khosrotehrani K, Aractingi S. Igf1r signalling acts on the anagen-to-catagen transition in the hair cycle. Exp Dermatol 2017; 26:785-791. [PMID: 28094870 DOI: 10.1111/exd.13287] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/27/2016] [Indexed: 12/17/2022]
Abstract
Insulin-like growth factor 1 (Igf1) is important for skin development and homoeostasis. However, overexpression and inactivation studies have produced variable findings regarding its role in hair follicle (HF) biology. Here, we studied a conditional and inducible knockout of the Igf1 receptor (Igf1r) in keratin 15-expressing bulge cells. Deletion of Igf1r after the development of the skin appendages in K15-Igf1rKO mice showed no abnormalities in epidermal homoeostasis. Numbers of bulge cells were lower in K15-Igf1rKO mice than in controls, without consequences on wound healing, at least in young mice. K15-Igf1rKO HFs entered anagen phase earlier than controls and showed a delay in the anagen/catagen switch. The expression of Bmp-4 mRNA was inhibited in HFs from K15-Igf1rKO . MED1 transcription was impaired in the epidermis of K15-Igf1rKO mice. These findings suggest that Igf1r controls the hair cycle, partly through Bmp-4 activation.
Collapse
|
68
|
Soutou B, Aractingi S. [Skin and pregnancy]. LA REVUE DU PRATICIEN 2017; 67:411-414. [PMID: 30512886] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Skin and pregnancy. Skin manifestations during pregnancy are common and diversified. Physiological changes are the most frequently reported. These changes mainly include hyperpigmentation, cutaneous signs of vascular proliferation or congestion, and striae distensae. Regression is spontaneous in post-partum but total clearance can be incomplete. Eventual treatment of resistant changes is reported until delivery or end of lactation. Specific dermatoses of pregnancy include polymorphic eruptions of pregnancy, atopic eczema of pregnancy, intrahepatic cholestasis and pemphigoid gestationis. It is mandatory, in any eczema-like or urticaria-like pruritic dermatose of pregnancy, to rule out pemphigoid gestationis, a rare auto-immune dermatose, by performing skin biopsy with direct immunofluorescence or an ELISA BP 180-NC16A. In case of generalized pruritis, serum bile salts levels should be tested in order to rule out intrahepatic cholestasis.
Collapse
|
69
|
Canlorbe G, Castela M, Bendifallah S, Wang Z, Lefevre M, Chabbert-Buffet N, Aractingi S, DaraÏ E, Méhats C, Ballester M. Micro-RNA signature of lymphovascular space involvement in type 1 endometrial cancer. Histol Histopathol 2016; 32:941-950. [PMID: 28000202 DOI: 10.14670/hh-11-859] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVE Lymphovascular space involvement (LVSI) is a major prognostic factor in type 1 endometrial cancer (EC). However, its use has been criticized because of poor subjectivity. MicroRNA signatures have recently been linked to EC pathologic characteristics. The aim of this study was to evaluate whether microRNA profiles of type 1 EC can be related to LVSI status and used as a tool to adapt therapy. STUDY DESIGN MicroRNA expression was assessed by chip analysis and qRT-PCR in 12 formalin-fixed paraffin-embedded grade 2 EC specimens with positive LVSI and in 12 specimens with negative LVSI. Various statistical analyses, including enrichment analysis and a minimum p-value approach, were performed. RESULTS The expression levels of microRNAs 34c-5p, -23b-5p, and 23c were significantly lower in the EC with positive LVSI compared to those with negative LVSI. Women with a microRNA-34c-5p fold change <0.15 were more likely to have positive LVSI status (92.3%) compared with those with a microRNA-34c-5p fold change >0.15 (0.0%), p<0.001. Furthermore, women with a microRNA-23b-5p fold change <0.51 were more likely to have positive LVSI status (90.0%) compared with those with a microRNA-23b-5p fold change >0.51 (21.4%), p=0.003. CONCLUSION This was the first study to investigate the relative expression of microRNA in type 1 EC according to LVSI status. This microRNA expression profile may provide a basis for further study of the microRNA function in EC, and be used as a diagnostic tool for LVSI status.
Collapse
|
70
|
Heidelberger V, Kramkimel N, Huillard O, Boudou-Rouquette P, Chanal J, Franck N, Mullaert J, Arrondeau J, Alexandre J, Blanchet B, Leroy K, Aractingi S, Dupin N, Goldwasser F. Une histoire naturelle lente est associée à un meilleur taux de réponse aux anti-PD1 dans le mélanome. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
71
|
Guegan S, Kadlub N, Picard A, Rouillé T, Charbel C, Coulomb A, How-Kit A, Fraitag S, Aractingi S, Fontaine R. Potentiel clonogénique et tumorigénique variable des nævus congénitaux mutés NRAS. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
72
|
Heidelberger V, Kramkimel N, Huillard O, Boudou-Rouquette P, Chanal J, Franck N, Arrondeau J, Alexandre J, Blanchet B, Leroy K, Aractingi S, Dupin N, Goldwasser F. La sarcopénie associée à un IMC>25kg/m2 est prédictive de toxicité sévère précoce sous anti-PD1 chez les patients atteints de mélanome. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
73
|
Frumholtz L, Laurent-Roussel S, Aumaître O, Maurier F, Carlotti A, Dallot A, Le Guenno G, Kemeny JL, Antunes L, Froment N, Fraitag S, London J, Mouthon L, Terris B, Le Jeunne C, Aractingi S, Guillevin L, Dupin N, Terrier B. Manifestations cutanées au cours des vascularites associées aux ANCA dans une cohorte de 1553 patients. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
74
|
Chanal J, Kramkimel N, Avril MF, Goldwasser F, Dupin N, Aractingi S. Tolérance des patients de plus de 85 ans traités par anti-PD1 dans le mélanome. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
75
|
Kramkimel N, Heidelberger V, Huillard O, Rouquette PB, Chanal J, Franck N, Arrondeau J, Alexandre J, Blanchet B, Mullaert J, Aractingi S, Dupin N, Goldwasser F. Slow natural history predicts higher response rate to nivolumab and pembrolizumab in advanced melanoma patients. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw379.21] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|